The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
22 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $14,532,417 in first-year total cost, median $700,952.
Most frequent study sections
- Cancer, Heart, and Sleep Epidemiology A Study Section[CHSA]3
- Clinical and Integrative Cardiovascular Sciences Study Section[CICS]3
- Clinical Integrative Cardiovascular and Hematological Sciences Study Section[CCHS]2
- Integrative Myocardial Physiology/Pathophysiology A Study Section [MPPA]2
- Myocardial Ischemia and Metabolism Study Section[MIM]2
Most frequent institutions
- KAISER FOUNDATION RESEARCH INSTITUTE3
- SLOAN-KETTERING INST CAN RESEARCH2
- UNIVERSITY OF PENNSYLVANIA2
- VANDERBILT UNIVERSITY MEDICAL CENTER2
- BECKMAN RESEARCH INSTITUTE/CITY OF HOPE1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2022 | Immune checkpoint inhibitors and accelerated coronary atherosclerosis1R01HL159187-01A1 | NEILAN, TOMAS G | MASSACHUSETTS GENERAL HOSPITAL, MA | $1,041,129 | CCHS |
| 2022 | Flexible versus Standard Aerobic Training Dosing in Primary Breast Cancer: A Randomized and Response-Adapted Trial1R01CA272733-01 | SCOTT, JESSICA | SLOAN-KETTERING INST CAN RESEARCH, NY | $734,548 | BMHO |
| 2022 | [18F]F-AraG as an imaging biomarker for early diagnosis and monitoring of cardiotoxicity related to doxorubicin and immune check point inhibitor therapy1R01HL160688-01 | LEVI, JELENASEO, YOUNGHO | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | $728,416 | CTIS |
| 2022 | Primary Prevention to Reduce Cardiovascular Morbidity and Optimize Cancer Outcomes1R01HL151665-01A1 | KAWATKAR, ANIKET A | KAISER FOUNDATION RESEARCH INSTITUTE, CA | $718,362 | HSQE |
| 2022 | Hemopexin as an Early Biomarker of Anthracycline Cardiac Toxicity1R01HL163172-01 | ASNANI, AARTI | BETH ISRAEL DEACONESS MEDICAL CENTER, MA | $672,532 | MPPA |
| 2022 | Cardiovascular Impact of Near-complete Estrogen Deprivation for Breast Cancer1R01HL159393-01A1 | JORDAN, JENNIFER HAWTHORNETHOMAS, ALEXANDRA | WAKE FOREST UNIVERSITY HEALTH SCIENCES, NC | $621,859 | CCHS |
| 2022 | Treatment-Related Cardiotoxicity in Children with Relapsed Acute Myeloid Leukemia - Natural History, Occurrence and Implications1R01HL164925-01 | GETZ, KELLY DIRINGER | UNIVERSITY OF PENNSYLVANIA, PA | $538,547 | CHSA |
| 2021 | Long-Term Cardiovascular Sequelae of Cancer Immunotherapies1R01HL155990-01 | JOHNSON, DOUGLAS BMOSLEHI, JAVID J | VANDERBILT UNIVERSITY MEDICAL CENTER, TN | $833,492 | CICS |
| 2021 | Immunologic and Antigenic Drivers of Immune Checkpoint Inhibitor-Associated Myocarditis1R01HL156021-01A1 | BALKO, JUSTIN MMOSLEHI, JAVID J | VANDERBILT UNIVERSITY MEDICAL CENTER, TN | $832,061 | AICS |
| 2021 | Risk prediction and longitudinal assessment of cardiotoxicity and functional capacity trajectory in NSCLC patients1R01HL157273-01 | LIAO, ZHONGXING | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $788,652 | CICS |
| 2021 | Cardioprotective Therapy for Doxorubicin Using iPSC Microtissue and CRISPR Screening1R01HL150693-01A1 | RAJADAS, JAYAKUMARWU, JOSEPH C. | STANFORD UNIVERSITY, CA | $627,358 | MPPA |
| 2021 | Reducing cardiac toxicity with deep learning and MRI-guided radiation therapy1R01HL153720-01A1 | GLIDE-HURST, CARRI KAYE | UNIVERSITY OF WISCONSIN-MADISON, WI | $524,106 | RTB |
| 2021 | A Multi-omics evaluation of Carfilzomib-related Cardiotoxicity1R01HL151659-01A1 | GONG, YAN | UNIVERSITY OF FLORIDA, FL | $433,446 | CHSB |
| 2021 | Inhibition of Radiation-Induced Coronary Microvascular Disease1R01HL150266-01A1 | POKHAREL, SARASWATI | ROSWELL PARK CANCER INSTITUTE CORP, NY | $420,500 | MIM |
| 2021 | Immunomodulation of Galectin-3 to Prevent Radiation-Induced Myocardial Fibrogenesis1R01HL152090-01A1 | SHARMA, UMESH C | STATE UNIVERSITY OF NEW YORK AT BUFFALO, NY | $279,125 | CCHF |
| 2020 | Primary Prevention to Reduce Cardiovascular Morbidity and Optimize Cancer Outcomes1R56HL151665-01 | KAWATKAR, ANIKET A | KAISER FOUNDATION RESEARCH INSTITUTE, CA | $810,138 | HSOD |
| 2020 | Prevention of Heart Failure induced by Doxorubicin with Early Administration of Dexrazoxane1R01HL151993-01 | CHANG, HUI-MING | UNIVERSITY OF MISSOURI-COLUMBIA, MO | $763,778 | CICS |
| 2020 | Mechanistic Risk Prediction of Radiation Therapy Cardiotoxicity1R01HL148272-01A1 | KY, BONNIE | UNIVERSITY OF PENNSYLVANIA, PA | $762,918 | CHSA |
| 2020 | Cardiovascular reserve capacity in survivors of hematopoietic cell transplantation1R01HL150069-01 | ARMENIAN, SARO | BECKMAN RESEARCH INSTITUTE/CITY OF HOPE, CA | $743,275 | CHSA |
| 2020 | A Randomized Trial to Minimize Non-Response to Aerobic Training in Operable Breast Cancer1R37CA248665-01 | SCOTT, JESSICA | SLOAN-KETTERING INST CAN RESEARCH, NY | $683,542 | BMIO |
| 2020 | PAR1 as a Therapeutic Target in Doxorubicin-induced Cardiotoxicity1R01HL148432-01A1 | ANTONIAK, SILVIO | UNIV OF NORTH CAROLINA CHAPEL HILL, NC | $563,165 | MIM |
| 2020 | Risk prediction of breast cancer treatment-related cardiotoxicity to guide clinical decision making1R01HL154319-01 | HAQUE, REINAPOTOSKY, ARNOLD L | KAISER FOUNDATION RESEARCH INSTITUTE, CA | $411,468 | NRCS |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.